The prognostic value of elimination rate constant K score of prostate-specific antigen in metastatic castration-resistant prostate cancer patients treated with docetaxel

IF 2.7 2区医学 Q2 UROLOGY & NEPHROLOGY

Prostate International Pub Date : 2025-06-01 DOI:10.1016/j.prnil.2024.11.007

Satı Coşkun Yazgan , Abdulkadir Sarı , Hatice Bölek , Emre Yekedüz , Yüksel Ürün

{"title":"The prognostic value of elimination rate constant K score of prostate-specific antigen in metastatic castration-resistant prostate cancer patients treated with docetaxel","authors":"Satı Coşkun Yazgan , Abdulkadir Sarı , Hatice Bölek , Emre Yekedüz , Yüksel Ürün","doi":"10.1016/j.prnil.2024.11.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>To evaluate the prognostic value of the elimination rate constant K (KELIM), a marker of chemosensitivity, in mCRPC patients treated with docetaxel.</div></div><div><h3>Materials and methods</h3><div>The study included patients who had received first-line docetaxel for mCRPC. The KELIM score was calculated using PSA measurements obtained within the first 100 days of chemotherapy. The patients were divided into two groups based on the KELIM levels: KELIM PSA <1 and KELIM PSA ≥1. The relationship between overall survival (OS) and the KELIM groups was evaluated.</div></div><div><h3>Results</h3><div>A total of 164 patients were included in this study. The median age was 68.1 years (interquartile range (IQR) 62.2-71.1). There were 76 and 88 patients in the KELIM PSA <1 and KELIM PSA ≥1 groups, respectively. The median OS in the KELIM PSA ≥1 group (46.2 months, 95% confidence interval (CI): 38.8–53.6) was found to be longer than in the KELIM PSA <1 group (32.0 months, 95% CI: 23.1–40.9) (<em>P</em> = 0.032). In multivariate analysis, the risk of death was independently higher in the KELIM PSA <1 group than in the KELIM PSA ≥1 group (Hazard Ratio (HR): 1.58, 95% CI: 1.02-2.43, <em>P</em> = 0.037).</div></div><div><h3>Conclusions</h3><div>Higher KELIM scores are positively correlated with improved overall survival in mCRPC patients treated with docetaxel.</div></div>","PeriodicalId":20845,"journal":{"name":"Prostate International","volume":"13 2","pages":"Pages 103-106"},"PeriodicalIF":2.7000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostate International","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2287888224000898","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

To evaluate the prognostic value of the elimination rate constant K (KELIM), a marker of chemosensitivity, in mCRPC patients treated with docetaxel.

Materials and methods

The study included patients who had received first-line docetaxel for mCRPC. The KELIM score was calculated using PSA measurements obtained within the first 100 days of chemotherapy. The patients were divided into two groups based on the KELIM levels: KELIM PSA <1 and KELIM PSA ≥1. The relationship between overall survival (OS) and the KELIM groups was evaluated.

Results

A total of 164 patients were included in this study. The median age was 68.1 years (interquartile range (IQR) 62.2-71.1). There were 76 and 88 patients in the KELIM PSA <1 and KELIM PSA ≥1 groups, respectively. The median OS in the KELIM PSA ≥1 group (46.2 months, 95% confidence interval (CI): 38.8–53.6) was found to be longer than in the KELIM PSA <1 group (32.0 months, 95% CI: 23.1–40.9) (P = 0.032). In multivariate analysis, the risk of death was independently higher in the KELIM PSA <1 group than in the KELIM PSA ≥1 group (Hazard Ratio (HR): 1.58, 95% CI: 1.02-2.43, P = 0.037).

Conclusions

Higher KELIM scores are positively correlated with improved overall survival in mCRPC patients treated with docetaxel.

查看原文本刊更多论文

多西紫杉醇治疗转移性去势抵抗性前列腺癌患者前列腺特异性抗原消除率常数K评分的预后价值

目的：评价多西紫杉醇治疗mCRPC患者化疗敏感性指标——消除速率常数K （KELIM）的预后价值。材料和方法本研究纳入了接受一线多西他赛治疗mCRPC的患者。KELIM评分是使用化疗前100天内获得的PSA测量值计算的。根据KELIM水平将患者分为KELIM PSA≥1组和KELIM PSA≥1组。评估KELIM组与总生存期（OS）的关系。结果本研究共纳入164例患者。中位年龄为68.1岁（四分位数间距（IQR） 62.2-71.1）。KELIM PSA≥1组76例，KELIM PSA≥1组88例。KELIM PSA≥1组的中位生存期（46.2个月，95%可信区间（CI）： 38.8-53.6）长于KELIM PSA≥1组（32.0个月，95% CI: 23.1-40.9）（P = 0.032）。在多因素分析中，KELIM PSA≥1组的独立死亡风险高于KELIM PSA≥1组（风险比（HR）： 1.58, 95% CI: 1.02-2.43, P = 0.037）。结论在多西他赛治疗的mCRPC患者中，较高的KELIM评分与总生存率的提高呈正相关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Prostate International Medicine-Urology

CiteScore

4.40

自引率

26.70%

发文量

审稿时长

35 days

期刊介绍： Prostate International (Prostate Int, PI), the official English-language journal of Asian Pacific Prostate Society (APPS), is an international peer-reviewed academic journal dedicated to basic and clinical studies on prostate cancer, benign prostatic hyperplasia, prostatitis, and ...